AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26942886
Drug: Matched cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched cohort (received no drugs predicted to be lack-of-benefit)
Trial: 26942886
Drug: Unmatched cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmatched cohort (received at least one drug predicted to be lack-of-benefit)
Trial: 26943275
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and paclitaxel chemotherapy
Trial: 26944694
Drug: Microcirculatory parameters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcirculatory parameters recorded using sublingual incident dark field microscopy and global flow measurements (oesophageal Doppler and transthoracic echocardiography).
Trial: 26944694
Drug: Sequential Organ
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Organ Failure Assessment scores analysis.
Trial: 26944863
Drug: Oral LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LNG 1.5 mg plus LNG 52 mg IUD
Trial: 26945556
Drug: Colonic confocal
RxNorm normalized name: COLON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic confocal laser endomicroscopy (CLE) after medical treatment escalation
Trial: 26945843
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg weekly)
Trial: 26947173
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg)
Trial: 26947173
Drug: Roxadustat and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat and Warfarin
Trial: 26947199
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/day, days 1-21 of a 28-day cycle (cohort 1)
Trial: 26947199
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/day continuously (cohort 2)
Trial: 26947199
Drug: Lenalidomide 35
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 35 mg/day continuously (cohort 3)
Trial: 26948580
Drug: 280 mg
RxNorm normalized name: levodopa 280 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg semagacestat
Trial: 26948683
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dexamethasone suppression test (DST)
Trial: 26949390
Drug: Continuous S(+)-ketamine
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous S(+)-ketamine infusion at a rate of 0.3 mg·kg(-1)·h(-1)
Trial: 26951043
Drug: RebiSmart(®) for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RebiSmart(®) for self-administering IFN β-1a 44 μg three times weekly
Trial: 26951310
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks
Trial: 26951410
Drug: Depot gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide
Trial: 26951627
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg once daily) combined with chemotherapy
Trial: 26951820
Drug: MRKAd5 HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRKAd5 HIV-1 Gag/Pol/Nef vaccine
Trial: 26952006
Drug: Resminostat plus
RxNorm normalized name: resminostat
DrugBank: Resminostat (DB12392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resminostat plus sorafenib (n=38); dosages ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib.
Trial: 26952006
Drug: Resminostat monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resminostat monotherapy (n=19); dosage was 600mg.
Trial: 26952546
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg, given every 3 weeks)
Trial: 26957532
Drug: Evidence-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medication use in-hospital and at discharge
Trial: 26960977
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg adenosine injected into the left atrium
Trial: 26960977
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg adenosine injected sequentially after 20 mg
Trial: 26960977
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg adenosine injected sequentially after 20 mg
Trial: 26960977
Drug: High-dose adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adenosine
Trial: 26962173
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake of 0.2 to 2.0 g ⋅ kg-1 ⋅ d-1, consumed hourly for 8 hours as an amino acid mixture with egg protein and L-[1-13C]phenylalanine as the indicator amino acid.
Trial: 26962173
Drug: Current intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current intake recommendations for dietary protein of 0.66 g ⋅ kg-1 ⋅ d-1 for EAR and 0.8 g ⋅ kg-1 ⋅ d-1 for RDA.
Trial: 26962179
Drug: Vitamin B-6
RxNorm normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-6 restriction (0.37 ± 0.04 mg/d)
Trial: 26962183
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (LA) 0.3 g/d
Trial: 26962183
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1.3 g/d
Trial: 26962189
Drug: Cocoa extract
RxNorm normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa extract (1.4 g/d, 645 mg total polyphenols/d)
Trial: 26962193
Drug: SQ-LNSs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNSs with 0 or 10 mg added zinc and placebo tablet
Trial: 26965296
Drug: FG-3019 administered
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks
Trial: 26965794
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with commonly used antimicrobials as per IDSA guidelines
Trial: 26965915
Drug: Romidepsin 14
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 14 mg/m² on days 1, 8, and 15 of six 28-day cycles; maintenance dosing twice per cycle after 12 cycles, and potentially reduced to once per cycle after 24 cycles for those who had received maintenance for ≥6 months.
Trial: 26965915
Drug: Romidepsin (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romidepsin (continuation of treatment for patients with SD),
Trial: 26966027
Drug: ASP3026 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3026 (oral ALK inhibitor) at doses of 25-800 mg once daily in 28-day cycles
Trial: 26966027
Drug: ASP3026 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3026 (oral ALK inhibitor)
Trial: 26966551
Drug: CAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAU plus IBD-specific cognitive-behavioural therapy (CBT)
Trial: 26966573
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) iron
Trial: 26966573
Drug: Overall antianemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall antianemic therapy
Trial: 26968374
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and laboratory parameters assessed daily for up to 6 days during acute illness and at a follow-up visit 1 week later.
Trial: 26968534
Drug: Idelalisib and
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib and entospletinib combination therapy
Trial: 26968708
Drug: EGFR-targeted CAR-T
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-targeted CAR-T cell infusions
Trial: 26971081
Drug: Sertraline 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 300 mg/day
Trial: 26971081
Drug: Sertraline (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (any dose)
Trial: 26971081
Drug: Sertraline 100-200
RxNorm normalized name: sertraline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100-200 mg/day
Trial: 26971192
Drug: Drug taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug taper
Trial: 26971192
Drug: Tapering to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering to no medications
Trial: 26971192
Drug: Trials requiring
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials requiring treatment resistance
Trial: 26971488
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of electrographic status epilepticus
Trial: 26971680
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of autologous bone marrow-derived mesenchymal stromal cells (MSCs) at a median dose of 1.2 × 10(6) MSCs/kg body weight, with 2-3 injections per patient.
Trial: 26971692
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 therapy
Trial: 26972567
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived endothelial progenitor cells (EPC), administered through the hepatic artery in a single administration.
Trial: 26973849
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (Perenterol forte 250 mg capsules, twice per day for 7 days after antibiotic discontinuation)
Trial: 26973849
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, twice per day for 7 days after antibiotic discontinuation)
Trial: 26974526
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg q24h
Trial: 26974526
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg q12h
Trial: 26974526
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (Period 1)
Trial: 26974547
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity levels (measured by daily step counts using accelerometry)
Trial: 26975937
Drug: Oral mixed-meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mixed-meal tolerance test (OMTT)
Trial: 26976424
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg intravenously once per week
Trial: 26976424
Drug: Temsirolimus 75
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 75 mg intravenously once per week
Trial: 26976424
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg and 75 mg cohorts
Trial: 26976799
Drug: ombitasvir co-formulated
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (with ribavirin for genotype 1a patients)
Trial: 26976799
Drug: ombitasvir co-formulated
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (without ribavirin for genotype 1b patients)
Trial: 26976799
Drug: Ribavirin therapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin therapy
Trial: 26976872
Drug: Echinocandins/L-AmB-based regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinocandins/L-AmB-based regimen
Trial: 26977746
Drug: Nucleoside-Sparing Regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside-Sparing Regimens with Raltegravir and a Boosted Protease Inhibitor
Trial: 26978384
Drug: Maternal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal blood lead level (BLL) > 50 µg/L
Trial: 26978384
Drug: Children's blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's blood lead level (BLL) > 50 µg/L
Trial: 26978775
Drug: Disposable intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disposable intranasal mucosal atomization device (DIMAD)
Trial: 26980473
Drug: Icotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (250 mg, three times daily)
Trial: 26980480
Drug: PepCan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PepCan 50 μg
Trial: 26980480
Drug: PepCan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PepCan 100 μg
Trial: 26981247
Drug: ONCOS-102 plus
RxNorm normalized name: ONCOS-102
DrugBank: ONCOS-102 (DB17274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONCOS-102 plus daily low-dose oral cyclophosphamide (CPO)
Trial: 26984445
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg) administered intravenously every 21 days for 3 cycles
Trial: 26984445
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg orally) as a positive control
Trial: 26987488
Drug: Rivaroxaban administered
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban administered within 30 days of the index stroke for secondary prevention of stroke
Trial: 26990620
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; IgG aPL levels significantly lower during the second and third trimesters compared to initial screening.
Trial: 26990620
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; IgM aPL titers were negative in the majority of patients and decreased modestly during pregnancy.
Trial: 26990620
Drug: Antiphospholipid antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; changes in aPL levels or aPL status.
Trial: 26990620
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant (LAC) presence.
Trial: 26991823
Drug: Palbociclib 100
RxNorm normalized name: palbociclib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 100 mg once daily (3 weeks on/1 week off)
Trial: 26991823
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg once daily (3 weeks on/1 week off)
Trial: 26991823
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg plus letrozole 2.5 mg
Trial: 26991823
Drug: Palbociclib 100
RxNorm normalized name: palbociclib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 100 mg
Trial: 26993070
Drug: Acute hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hypoglycemia (2.8 mmol/L) during a hyperinsulinemic euglycemic-hypoglycemic glucose clamp after an overnight fast.
Trial: 26993070
Drug: Healthy control
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy control subjects (n = 7) during acute hypoglycemia (2.8 mmol/L).
Trial: 26993070
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with normal awareness of hypoglycemia (NAH) during acute hypoglycemia (2.8 mmol/L).
Trial: 26993071
Drug: Model-based method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based method to estimate hepatic and extrahepatic insulin clearance
Trial: 26993131
Drug: dHER2 immunotherapeutic
RxNorm normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dHER2 immunotherapeutic (20, 100, 500 µg) combined with AS15
Trial: 26993131
Drug: dHER2 immunotherapeutic
RxNorm normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dHER2 immunotherapeutic (500 µg) with the most intense immunization schedule
Trial: 26993266
Drug: Agalsidase β
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase β (1 mg/kg every 2 weeks)
Trial: 26993869
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical stimulation at a current twice their motor threshold, at 1 Hz, for 5 minutes.
Trial: 26998426
Drug: CT+G (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT+G (chemotherapy plus goserelin)
Trial: 26998426
Drug: CT (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (chemotherapy only)
Trial: 26999488
Drug: Antiangiogenic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic therapy
Trial: 27001822
Drug: M-EDTA-EtOH lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-EDTA-EtOH lock solution administered once daily for 2 hours for a total of 7 doses.
Trial: 27001822
Drug: M-EDTA-EtOH lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-EDTA-EtOH lock solution.
Trial: 27003363
Drug: Pazopanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib plus CapeOx (capecitabine 850 mg/m2 bid, day 1-14; oxaliplatin 130 mg/m2, day 1; pazopanib 800 mg, day 1-21)
Trial: 27004234
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid collection for antibody detection
Trial: 27004241
Drug: Day-3 subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-3 subgroup (72-hour PPI infusion)
Trial: 27004241
Drug: Day-2 subgroup
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-2 subgroup (one day early PPI infusion)
Trial: 27004241
Drug: Endoscopic epinephrine-injection
RxNorm normalized name: epinephrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic epinephrine-injection monotherapy
Trial: 27004241
Drug: Hypoalbuminemia <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoalbuminemia < 3.0 g/dL
Trial: 27004241
Drug: Hypoalbuminemia <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoalbuminemia < 3.5 g/dL
Trial: 27005892
Drug: Autologous cell
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cell therapy using CD133+ bone marrow-derived stem cells (BMDSCs) in conjunction with hormonal replacement therapy
Trial: 27006491
Drug: Nilotinib therapy
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib therapy
Trial: 27006492
Drug: TIL infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIL infusion followed by attenuated doses of IL2 administered in an intravenous, continuous decrescendo regimen
Trial: 27006492
Drug: TIL infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIL infusion followed by attenuated doses of IL2